Locally delivered rhTGF‐β2 enhances bone ingrowth and bone regeneration at local and remote sites of skeletal injury
- 1 January 2001
- journal article
- Published by Wiley in Journal of Orthopaedic Research
- Vol. 19 (1), 85-94
- https://doi.org/10.1016/s0736-0266(00)00015-2
Abstract
The purposes of the present study were to determine if recombinant human transforming growth factor-beta-2 (rhTGF-β2) enhances bone ingrowth into porous-coated implants and bone regeneration in gaps between the implant and surrounding host bone. The implants were placed bilaterally for four weeks in the proximal humeri of skeletally mature, adult male dogs in the presence of a 3-mm gap. In three treatment groups of animals, the test implant was treated with hydroxyapatite/tricalcium phosphate (HA/TCP) and rhTGF-β2 in buffer at a dose per implant of 1.2 μg (n = 6), 12 μg (n = 7), or 120 μg (n = 7) and placed in the left humerus. In these same animals, an internal control implant treated only with HA/TCP and buffer was placed in the right humerus. In a non-TGF-β treated external control group of animals (n = 7), one implant was treated with HA/TCP while the contralateral implant was not treated with the ceramic. In vitro analyses showed that approximately 15% of the applied dose was released within 120 h with most of the release occurring in the first 24 h. The TGF-μ treated implants had significantly more bone ingrowth than the controls with the greatest effect in the 12 μg/implant group (a 2.2-fold increase over the paired internal control (P = 0.004) and a 4-fold increase over the external control (P < 0.001)). The TGF-β treated implants had significantly more bone formation in the gap than the controls with the greatest effect in the 12 and 120 μg groups (1.8-fold increases over the paired internal controls (P = 0.003 and P = 0.012, respectively) and 2.8-fold increases over the external controls (P < 0.001 and P = 0.001, respectively)). Compared to the external controls, the internal control implants tended to have more bone ingrowth (1.9-fold increase, P = 0.066) and had significantly more bone formation in the gap (1.7-fold increase, P = 0.008). Thus, application of rhTGF-β2 to a porous-coated implant-stimulated local bone ingrowth and gap healing in a weakly dose-dependent manner and stimulated bone regeneration in the 3-mm gap surrounding the contralateral control implant, a site remote from the local treatment with the growth factor. © 2001 Orthopaedic Research Society. Published by Elsevier Science Ltd. All rights reserved.Keywords
This publication has 42 references indexed in Scilit:
- Transforming growth factor‐β1 enhances bone healing to unloaded tricalcium phosphate coated implants: An experimental study in dogsJournal of Orthopaedic Research, 1996
- Systemic administration of transforming growth factor-beta 2 prevents the impaired bone formation and osteopenia induced by unloading in rats.JCI Insight, 1995
- Polypeptide factors regulating osteogenesis and bone marrow repairJournal of Cellular Biochemistry, 1994
- Stimulation of bone healing by transforming growth factor‐beta1 released from polymeric or ceramic implantsJournal of Applied Biomaterials, 1994
- Controlled release of TGF-β1 from a biodegradable matrix for bone regenerationJournal of Biomaterials Science, Polymer Edition, 1994
- Local injection of TGF-β increases the strength of tibial fractures in the ratActa Orthopaedica, 1994
- Histomorphometric assessment of the mechanisms for rapid ingrowth of bone to HA/TCP coated implantsJournal of Biomedical Materials Research, 1993
- Transforming growth factor-β enhances fracture healing in rabbit tibiaeActa Orthopaedica, 1993
- Improving the accuracy of trabecular width measurementsBone, 1992
- Rapid publication TGF-β1 induces bone closure of skull defectsJournal of Bone and Mineral Research, 1991